N-(2-Methoxy-ethyl)-4-[4-(6-phenylsulfanyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-benzenesulfonamide

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N-(2-Methoxy-ethyl)-4-[4-(6-phenylsulfanyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-benzenesulfonamide
• 英文别名: Imidazo[1,2-a]pyridine deriv. 4g；N-(2-methoxyethyl)-4-[[4-(6-phenylsulfanylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]benzenesulfonamide
• 化学式: C₂₆H₂₄N₆O₃S₂
• 分子量: 532.647
• InChiKey: AKKYFIFRTKACRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  sodium thiophenolate 、 4-[4-(6-Bromo-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-N-(2-methoxy-ethyl)-benzenesulfonamide 生成 N-(2-Methoxy-ethyl)-4-[4-(6-phenylsulfanyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-benzenesulfonamide
  参考文献：
  名称：

  Imidazo[1,2- a ]pyridines. Part 2 : SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors

  摘要：

  Exploration of SAR and optimisation of the imidazo[1,2-a]pyridine CDK inhibitors has lead to the discovery of novel, potent and selective inhibitors of the cyclin-dependent kinase CDK2. Understanding of SAR has identified positions Of Substitution, which allow modification of physical properties and offer the potential for in vivo optimisation. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.015

文献信息

• Imidazo[1,2- a ]pyridines. Part 2 : SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors
  作者：Kate F Byth、Janet D Culshaw、Stephen Green、Sandra E Oakes、Andrew P Thomas

  DOI：10.1016/j.bmcl.2004.02.015

  日期：2004.5

  Exploration of SAR and optimisation of the imidazo[1,2-a]pyridine CDK inhibitors has lead to the discovery of novel, potent and selective inhibitors of the cyclin-dependent kinase CDK2. Understanding of SAR has identified positions Of Substitution, which allow modification of physical properties and offer the potential for in vivo optimisation. (C) 2004 Elsevier Ltd. All rights reserved.